Skoči na glavni sadržaj

Acta clinica Croatica, Vol. 64. No. 4, 2025.

Stručni rad

https://doi.org/10.20471/acc.2025.64.04.19

Erenumab in the Prevention of Migraine Headaches – A Pilot Study

Marina Titlić ; Department of Neurology, University Hospital Split, Split, Croatia; School of Medicine, University of Split, Split, Croatia
Ana Ćurković Katić orcid id orcid.org/0009-0007-4475-7119 ; Department of Neurology, University Hospital Split, Split, Croatia *
Rinaldo Romac ; Department of Neurology, University Hospital Split, Split, Croatia; School of Medicine, University of Split, Split, Croatia
Mario Mihalj orcid id orcid.org/0000-0001-5609-4868 ; Department of Neurology, University Hospital Split, Split, Croatia; School of Medicine, University of Split, Split, Croatia

* Dopisni autor.

Puni tekst: engleski pdf 209 Kb

str. 823-827

preuzimanja: 96

citiraj

Sažetak

This research aimed to assess the efficiency of erenumab (Aimovig) in the preventive
treatment of patients with episodic and chronic migraines. In Croatia, migraine prevention is applied
to patients with ≥ 4 days of migraine headaches per month. Prevention efficiency was assessed with the
Migraine Disability Assessment Test (MIDAS) scale. The research included 26 subjects, comprising 25
women and 1 man. The mean duration of migraine headache in our patients was 13 ± 1.8 years. All the
patients had already been taking ≥ 2 preventive medication therapies and most of them had also been
subjected to acupuncture and/or neurofeedback therapies, but with no significant effect. The MIDAS
mean value at the first examination, i.e. one week before starting preventive erenumab therapy, was 17.69.
The MIDAS scale mean value six months after migraine preventive therapy with 70 mg erenumab
subcutaneously (SC) was 4.81. Thus, disability was decreased by almost 75%, which is deemed to be
significant. Only one subject had no improvement in six months, wherefore we increased his dosage
of erenumab to 140 mg SC. With the increased drug dosage and elimination of exogenous triggering
factors, the effect was significant, with a significant decrease of disability (MIDAS 4) in the following
three months.

Ključne riječi

Erenumab; CGRP; Migraine; Prevention

Hrčak ID:

344733

URI

https://hrcak.srce.hr/344733

Datum izdavanja:

31.12.2025.

Podaci na drugim jezicima: hrvatski

Posjeta: 290 *